A fecal immunochemical test (FIT) conducted 2 years apart could form the basis for population-based colorectal cancer screening if this approach goes on to show a mortality benefit, according to a preliminary analysis.
Researchers are investigating the effect of this timeframe of FIT screening as well as a single colonoscopy on colorectal cancer incidence and mortality as the primary endpoints of a randomized controlled trial called SCREESCO. Both were compared to a control of no intervention.